Natural and endogenous compounds that are metabolized by CYP2C8
| Substrate | Description | Metabolic Pathway(s) Catalyzed by CYP2C8 | Other CYP Enzymes Involved in Overall Metabolisma | References |
|---|---|---|---|---|
| 1-Hydroxyl-2,3,5-trimethoxyxanthone | Constituent of Halenia elliptica | M1-M4 formation | CYP3A4, CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2C19 | Feng et al., 2014 |
| 7α- and 7β-Hydroxy-Δ8-THC | Marijuana constituent | Oxidation | CYP3A4, CYP2C9 | Watanabe et al., 2007 |
| 8-Prenylnaringenin (flavaprenin) | Prenylflavonoid | M2 formation | CYP2C19 | Guo et al., 2006 |
| Arachidonic acid | Endogenous compound | CYP2C9, CYP1A2, CYP2E1, CYP2J2 | Daikh et al., 1994; Rifkind et al., 1995; Zeldin et al., 1995; Barbosa-Sicard et al., 2005 | |
| Eicosapentaenoic acid | Endogenous compound | CYP2C9/11/23 | Barbosa-Sicard et al., 2005 | |
| Eupatilin | Flavone | 4-O-demethylation | CYP1A2 | Lee et al., 2007 |
| R/S-Limonene | Terpene | CYP2C19, CYP2C9, CYP3A4 | Miyazawa et al., 2002 | |
| Magnolin | Constituent of Shin-i | O-demethylation (M1 and M2), hydroxylation (M4) | CYP2C9, CYP2C19, CYP3A4 | Kim et al., 2011a |
| Mesaconitine | Alkaloid | M1-M2, M7-M9 formation | CYP3A4, CYP2C9, CYP2D6 | Ye et al., 2011 |
| Nitidine chloride | Alkaloid | CYP3A4 | Li et al., 2014b | |
| Silybin (silibinin) | Flavonolignan | O-demethylation | (CYP3A4) | Jancova et al., 2007 |
| Tanshinol borneol ester | Combination of the natural compounds danshensu and borneol | M1-M5 formation | (CYP3A4) | Liu et al., 2010b |
THC, tetrahydrocannabinol.
↵a This information is either based on the references given in the table or on data from the UW Metabolism and Transport Drug Interaction Database (DIDB), Copyright University of Washington 1999-2015 (DIDB Accessed May-September, 2015).